FASLODEX® (fulvestrant) Injection for intramuscular administration is an estrogen receptor antagonist without known agonist effects. The chemical name is 7-alpha-[9-(4,4,5,5,5-penta fluoropentylsulphinyl) nonyl]estra-1,3,5-(10)- triene-3,17-beta-diol.
FASLODEX is indicated for the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
Media Articles Related to Faslodex (Fulvestrant)
Faslodex and tamoxifen combo reverse tamoxifen-resistant breast cancer
Source: Lupus News From Medical News Today [2014.06.17]
The inexpensive anti-malarial drug hydroxychloroquine (HCQ) reverses resistance to tamoxifen, a widely used breast cancer drug, in mice.
Breast Cancer Quiz: Test Your Medical IQ
Source: MedicineNet Breast Lumps In Women Specialty [2015.01.23]
Title: Breast Cancer Quiz: Test Your Medical IQ
Category: MedicineNet Quiz
Created: 10/11/2010 3:00:00 PM
Last Editorial Review: 1/23/2015 6:00:08 PM
Palbociclib for Breast Cancer Inches Toward FDA Approval
Source: Medscape Hematology-Oncology Headlines [2015.01.21]
Palbociclib, the first CDK 4/6 inhibitor, has shown a doubling of progression-free survival in postmenopausal women with ER-positive, HER2-negative advanced-stage breast cancer.
Medscape Medical News
Scientist investigating mutation link to breast cancer drug resistance
Source: Breast Cancer News From Medical News Today [2015.01.20]
A leading scientist is investigating how oestrogen receptor (ER) mutations can cause drug resistance in secondary breast cancer patients receiving anti-hormone treatments such as tamoxifen.
Poor metabolic health increases risk for postmenopausal breast cancer irrespective of BMI
Source: Breast Cancer News From Medical News Today [2015.01.19]
Postmenopausal women who were metabolically unhealthy, as assessed by insulin abnormalities, were at increased risk for breast cancer compared with their metabolically healthy counterparts...
Published Studies Related to Faslodex (Fulvestrant)
Ganitumab with either exemestane or fulvestrant for postmenopausal women with
advanced, hormone-receptor-positive breast cancer: a randomised, controlled,
double-blind, phase 2 trial. 
hormone-receptor-positive breast cancer... INTERPRETATION: Addition of ganitumab to endocrine treatment in women with
Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial. [2011.01]
BACKGROUND AND PURPOSE: Fulvestrant, an oestrogen receptor (ER) antagonist with no known agonist effects, has shown activity in postmenopausal patients with ER-positive advanced breast cancer recurring or progressing following prior endocrine therapy. This double-blind, double-dummy, randomised phase III study (NCT00327769) was designed to compare the efficacy and safety of fulvestrant versus anastrozole in advanced breast cancer of Chinese postmenopausal women whose disease has progressed following prior endocrine treatment... CONCLUSIONS: These data demonstrate that fulvestrant 250 mg and anastrozole were similarly effective and well tolerated in the treatment of postmenopausal Chinese women with advanced breast cancer whose disease had progressed or recurred on prior endocrine treatment.
Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast
cancer: results of a multicentre, double-blind, randomised phase III trial. 
whose disease has progressed following prior endocrine treatment... CONCLUSIONS: These data demonstrate that fulvestrant 250 mg and anastrozole were
Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1). [2010.12]
BACKGROUND: FINDER1 compared efficacy, tolerability and pharmacokinetics (PK) of three fulvestrant dose regimens in postmenopausal Japanese women with estrogen receptor (ER)-positive locally advanced/metastatic breast cancer recurring or progressing after prior endocrine therapy... CONCLUSION: Fulvestrant AD, LD and HD had similar efficacy and tolerability profiles in postmenopausal Japanese women with ER-positive advanced breast cancer.
Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. [2010.10.20]
PURPOSE: We compared fulvestrant 500 mg regimen with the approved dose of fulvestrant 250 mg per month for treatment of postmenopausal women with estrogen receptor-positive advanced breast cancer who experienced progression after prior endocrine therapy... CONCLUSION: Fulvestrant 500 mg was associated with a statistically significant increase in PFS and not associated with increased toxicity, corresponding to a clinically meaningful improvement in benefit versus risk compared with fulvestrant 250 mg.
Clinical Trials Related to Faslodex (Fulvestrant)
Fulvestrant (FASLODEX™) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer [Completed]
The purpose of this study is to evaluate fulvestrant in the preliminary stage of breast
cancer treatment and assess the relationship between dose, exposure, degree of reduction in
tumor markers, and efficacy in postmenopausal women with estrogen receptor positive disease.
Comparison of Fulvestrant (FASLODEX™) 250 mg and 500mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy. [Active, not recruiting]
The purpose of this study is to evaluate the efficacy of a new dose of 500 mg Fulvestrant
with the standard dose of 250 mg in postmenopausal women with estrogen receptor positive
advanced breast cancer who have failed on a previous endocrine treatment.
Faslodex and Herceptin, Alone and Combined [Recruiting]
The purpose of this study is to evaluate the the relative anti-tumor efficacy of combined Faslodex and Herceptin therapy as compared with that of Faslodex or Herceptin given alone for first-line treatment in patients with metastatic breast cancer.
The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer [Active, not recruiting]
The purpose of this study is to compare the efficacy of Faslodex (fulvestrant) to Aromasin
(exemestane) in hormone receptor positive postmenopausal women with advanced breast cancer.
Patients will be treated until disease progression or until the investigator has determined
that treatment is not in the best interest of the patient, whichever occurs first.
Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor [Recruiting]
The purpose of this study is to find out what effect the combination of fulvestrant
(Faslodex) and dasatinib (Sprycel) has on advanced breast cancer compared to fulvestrant
Reports of Suspected Faslodex (Fulvestrant) Side Effects
Injection Site Pain (21),
Back Pain (17),
Pain in Extremity (15),
Disease Progression (14),
Hot Flush (13), more >>